Nervgen Pharma Corp Stock Price To Sales
| NGEN Stock | CAD 3.09 0.11 3.69% |
NervGen Pharma Corp fundamentals help investors to digest information that contributes to NervGen Pharma's financial success or failures. It also enables traders to predict the movement of NervGen Stock. The fundamental analysis module provides a way to measure NervGen Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NervGen Pharma stock.
| Last Reported | Projected for Next Year |
NervGen | Price To Sales |
NervGen Pharma Corp Company Price To Sales Analysis
NervGen Pharma's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
NervGen Price To Sales Driver Correlations
Understanding the fundamental principles of building solid financial models for NervGen Pharma is extremely important. It helps to project a fair market value of NervGen Stock properly, considering its historical fundamentals such as Price To Sales. Since NervGen Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of NervGen Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of NervGen Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, NervGen Pharma Corp has a Price To Sales of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to sales for all Canada stocks is 100.0% higher than that of the company.
NervGen Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NervGen Pharma's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NervGen Pharma could also be used in its relative valuation, which is a method of valuing NervGen Pharma by comparing valuation metrics of similar companies.NervGen Pharma is currently under evaluation in price to sales category among its peers.
NervGen Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of NervGen Pharma from analyzing NervGen Pharma's financial statements. These drivers represent accounts that assess NervGen Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of NervGen Pharma's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Enterprise Value | 44.9M | 46.7M | 66.0M | 90.3M | 81.3M | 47.2M |
NervGen Fundamentals
| Return On Equity | -2.3 | ||||
| Return On Asset | -0.53 | ||||
| Current Valuation | 196.37 M | ||||
| Shares Outstanding | 70.31 M | ||||
| Shares Owned By Insiders | 22.91 % | ||||
| Shares Owned By Institutions | 0.06 % | ||||
| Number Of Shares Shorted | 199.54 K | ||||
| Price To Book | 23.67 X | ||||
| EBITDA | (19.24 M) | ||||
| Net Income | (22.38 M) | ||||
| Cash And Equivalents | 8.27 M | ||||
| Cash Per Share | 0.30 X | ||||
| Total Debt | 15.25 M | ||||
| Current Ratio | 25.72 X | ||||
| Book Value Per Share | (0.03) X | ||||
| Cash Flow From Operations | (11.3 M) | ||||
| Short Ratio | 4.77 X | ||||
| Earnings Per Share | (0.39) X | ||||
| Target Price | 4.5 | ||||
| Beta | 1.35 | ||||
| Market Capitalization | 217.25 M | ||||
| Total Asset | 13.24 M | ||||
| Retained Earnings | (78.15 M) | ||||
| Working Capital | (2.62 M) | ||||
| Net Asset | 13.24 M |
About NervGen Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NervGen Pharma Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NervGen Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NervGen Pharma Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for NervGen Stock Analysis
When running NervGen Pharma's price analysis, check to measure NervGen Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NervGen Pharma is operating at the current time. Most of NervGen Pharma's value examination focuses on studying past and present price action to predict the probability of NervGen Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NervGen Pharma's price. Additionally, you may evaluate how the addition of NervGen Pharma to your portfolios can decrease your overall portfolio volatility.